Trial · NCT00679354
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Objective Response to Cilengitide | Treatment (Cilengitide) | With Objective Response | 1 | participants | |
| Objective Response to Cilengitide | Treatment (Cilengitide) | Without Objective Response | 23 | participants | |
| Time to Tumor Progression (TTP) | Treatment (Cilengitide) | 28 | Inter-Quartile Range 25 to 41 | Days | |
| Time to Treatment Failure (TTF) | Treatment (Cilengitide) | 28 | Inter-Quartile Range 25 to 41 | Days | |
| Time to Death (TTD) | Treatment (Cilengitide) | 172 | Inter-Quartile Range 99 to 226 | Days | |
| Rate of Toxicity, Especially That of Symptomatic Intratumoral Hemorrhage (ITH) Assessed by Common Terminology Criteria for Adverse Events Version 4.0 | Treatment (Cilengitide) | 6.9 | percent of pts with symptomatic ITH | ||
| Pharmacokinetic Parameter of Cilengitide in Plasma: Volume of Central Compartment (Vc) | Treatment (Cilengitide) | 6.20 | Full Range 3.34 to 10.72 | L/m^2 | |
| Pharmacokinetic Parameter of Cilengitide in Plasma: Elimination Rate Constant (Ke) | Treatment (Cilengitide) | 0.58 | Full Range 0.36 to 1.00 | hr^(-1) | |
| Pharmacokinetic Parameter of Cilengitide in Plasma: Half-life (t1/2) | Treatment (Cilengitide) | 1.26 | Full Range 0.69 to 1.90 | hours | |
| Pharmacokinetic Parameter of Cilengitide in Plasma: Systemic Clearance (Cl) | Treatment (Cilengitide) | 3.84 | Full Range 2.47 to 5.75 | L/hr/m^2 | |
| Pharmacogenetic Polymorphism in Drug Transporter Gene ABCB1 and Relate to Cilengitide Disposition as Measured by AUC | Treatment (Cilengitide) | 0.00 | Spearman's correlation | ||
| Pharmacogenetic Polymorphism in Drug Transporter Gene ABCB1 and Relate to Cilengitide Disposition as Measured by Systemic Clearance | Treatment (Cilengitide) | 0.56 | Spearman's Correlation | ||
| Pharmacogenetic Polymorphism in Drug Transporter Gene ABCG2 and Relate to Cilengitide Disposition as Measured by AUC | Treatment (Cilengitide) | -0.22 | Spearman's Correlation | ||
| Pharmacogenetic Polymorphism in Drug Transporter Gene ABCG2 and Relate to Cilengitide Disposition as Measured by Systemic Clearance | Treatment (Cilengitide) | -0.48 | Spearman's Correlation |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00679354/results